CCAR1 Rabbit Polyclonal Antibody
To Order : [email protected]
 CCAR1 Polyclonal Antibody |
|
ABP58004-003ml |
Abbkine |
0.03ml |
EUR 189.6 |
|
|
|
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920 |
CCAR1 Polyclonal Antibody |
|
ABP58004-01ml |
Abbkine |
0.1ml |
EUR 346.8 |
|
|
|
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920 |
CCAR1 Polyclonal Antibody |
|
ABP58004-02ml |
Abbkine |
0.2ml |
EUR 496.8 |
|
|
|
Description: A polyclonal antibody for detection of CCAR1 from Human, Mouse. This CCAR1 antibody is for WB, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CCAR1 protein at amino acid sequence of 840-920 |
 CCAR1 polyclonal antibody |
|
BS8140 |
Bioworld Biotech |
50ul |
EUR 358 |
|
|
|
Description: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
CCAR1 Polyclonal Antibody |
|
E-AB-14953-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CCAR1 Polyclonal Antibody |
|
E-AB-14953-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CCAR1 Polyclonal Antibody |
|
E-AB-14953-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CCAR1 Polyclonal Antibody |
|
E-AB-14953-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
CCAR1 Polyclonal Antibody |
|
BT-AP14733-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
|
|
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors., |
CCAR1 Polyclonal Antibody |
|
BT-AP14733-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
|
|
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors., |
CCAR1 Polyclonal Antibody |
|
BT-AP14733-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
|
|
Description: May be involved in apoptosis signaling in the presence of the reinoid CD437. Apoptosis induction involves sequestration of 14-3-3 protein(s) and mediated altered expression of multiple cell cycle regulatory genes including MYC, CCNB1 and CDKN1A. Plays a role in cell cycle progression and/or cell proliferation.,PTM:Phosphorylated upon DNA damage, probably by ATM or ATR.,sequence Contaminating sequence. Potential poly-A sequence.,Contains 1 SAP domain.,tissue specificity:Expressed in various epithelial cancer cell lines, including breast, colon, prostate, pancreatic and leukemia. Expression is regulated by growth factors., |
CCAR1 Polyclonal Antibody |
|
E11-201559 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CCAR1 Polyclonal Antibody |
|
JOT-AP14733-100ul |
Jotbody |
100ul |
EUR 220 |
|
|
CCAR1 Polyclonal Antibody |
|
JOT-AP14733-50ul |
Jotbody |
50ul |
EUR 144 |
|
|
CCAR1 Polyclonal Antibody |
|
E44H09166 |
EnoGene |
100ul |
EUR 255 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CCAR1 Polyclonal Antibody |
|
E913595 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CCAR1 Polyclonal Antibody |
|
MBS2527945-002mL |
MyBiosource |
0.02mL |
EUR 135 |
CCAR1 Polyclonal Antibody |
|
MBS2527945-006mL |
MyBiosource |
0.06mL |
EUR 190 |
CCAR1 Polyclonal Antibody |
|
MBS2527945-012mL |
MyBiosource |
0.12mL |
EUR 265 |
CCAR1 Polyclonal Antibody |
|
MBS2527945-02mL |
MyBiosource |
0.2mL |
EUR 415 |
CCAR1 Polyclonal Antibody |
|
MBS2527945-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1835 |
CCAR1 Polyclonal Antibody |
|
MBS9133629-002mL |
MyBiosource |
0.02mL |
EUR 200 |
CCAR1 Polyclonal Antibody |
|
MBS9133629-005mL |
MyBiosource |
0.05mL |
EUR 255 |
CCAR1 Polyclonal Antibody |
|
MBS9133629-01mL |
MyBiosource |
0.1mL |
EUR 345 |
CCAR1 Polyclonal Antibody |
|
MBS9133629-02mL |
MyBiosource |
0.2mL |
EUR 545 |
CCAR1 Polyclonal Antibody |
|
MBS9133629-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
CCAR1 Polyclonal Antibody |
|
MBS9125391-002mL |
MyBiosource |
0.02mL |
EUR 200 |
CCAR1 Polyclonal Antibody |
|
MBS9125391-005mL |
MyBiosource |
0.05mL |
EUR 255 |
CCAR1 Polyclonal Antibody |
|
MBS9125391-01mL |
MyBiosource |
0.1mL |
EUR 345 |
CCAR1 Polyclonal Antibody |
|
MBS9125391-02mL |
MyBiosource |
0.2mL |
EUR 545 |
CCAR1 Polyclonal Antibody |
|
MBS9125391-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
CCAR1 Polyclonal Antibody |
|
MBS8568311-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CCAR1 Polyclonal Antibody |
|
MBS8568311-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CCAR1 Polyclonal Antibody |
|
MBS8568311-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CCAR1 Polyclonal Antibody |
|
MBS8568311-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CCAR1 Polyclonal Antibody |
|
MBS8568311-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
CCAR1 Polyclonal Antibody |
|
MBS8530913-01mg |
MyBiosource |
0.1mg |
EUR 305 |
CCAR1 Polyclonal Antibody |
|
MBS8530913-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
CCAR1 Polyclonal Antibody |
|
MBS8530913-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
CCAR1 Polyclonal Antibody |
|
MBS8530913-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
CCAR1 Polyclonal Antibody |
|
MBS8530913-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
CCAR1 Polyclonal Antibody |
|
RD78024A-120uL |
Reddot Biotech |
120μL |
EUR 360 |
|
|
|
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE. |
CCAR1 Polyclonal Antibody |
|
RD78024A-200uL |
Reddot Biotech |
200μL |
EUR 630 |
|
|
|
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE. |
CCAR1 Polyclonal Antibody |
|
RD78024A-20uL |
Reddot Biotech |
20μL |
EUR 109.5 |
|
|
|
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE. |
CCAR1 Polyclonal Antibody |
|
RD78024A-60uL |
Reddot Biotech |
60μL |
EUR 214.5 |
|
|
|
Description: Cell division cycle and apoptosis regulator protein 1is aproteinthat in humans is encoded by theCCAR1gene. The deduced 1,150-amino acid CARP1 protein contains a putative cold-shock protein domain expected to bind RNA and a putative DNA-binding motif predicted to be involved in chromosomal organization. Immunohistochemical analysis detected CARP1 in the perinuclear compartment of human breast cancer cells, and the protein had an apparent molecular mass of 130 kD by SDS-PAGE. |
CCAR1 Polyclonal Antibody |
|
UB-GEN-6292 |
UpingBio |
100 ul |
EUR 200 |
 CCAR2 Rabbit Polyclonal Antibody |
|
E10G13710 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CCAR2 Rabbit Polyclonal Antibody |
|
E10G06826 |
EnoGene |
100 μl |
EUR 275 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
) Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1491743-005mL |
MyBiosource |
0.05mL |
EUR 190 |
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1491743-01mL |
MyBiosource |
0.1mL |
EUR 270 |
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1491743-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1499980-005mL |
MyBiosource |
0.05mL |
EUR 190 |
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1499980-01mL |
MyBiosource |
0.1mL |
EUR 270 |
Rabbit anti-human Cell division cycle and apoptosis regulator protein 1 polyclonal Antibody(CCAR1) |
|
MBS1499980-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
 (IHC,ELISA)) Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA) |
|
IRBAMLCCAR1AP953120UL |
Innovative research |
each |
EUR 259 |
|
|
|
Description: Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA) |
Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA) |
|
IRBAMLCCAR1AP953200UL |
Innovative research |
each |
EUR 403 |
|
|
|
Description: Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4) (IHC,ELISA) |
(IHC, ELISA)) Rabbit Anti CCAR1 Polyclonal Affinity Purified (PBS with 0.05% sodium azide and 50% glycerol, pH7.4)(IHC, ELISA) |
|
MBS8423047-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 CCAR1 Rabbit pAb |
|
A13595 |
Abclonal |
100μL |
EUR 623.48 |
CCAR1 Rabbit pAb |
|
A13595-100ul |
Abclonal |
100 ul |
EUR 369.6 |
CCAR1 Rabbit pAb |
|
A13595-200ul |
Abclonal |
200 ul |
EUR 550.8 |
CCAR1 Rabbit pAb |
|
A13595-20ul |
Abclonal |
20 ul |
EUR 219.6 |
CCAR1 Rabbit pAb |
|
A13595-50ul |
Abclonal |
50 ul |
EUR 267.6 |
CCAR1 Rabbit pAb |
|
A6334 |
Abclonal |
100μL |
EUR 1246.96 |
CCAR1 Rabbit pAb |
|
A6334-100ul |
Abclonal |
100 ul |
EUR 369.6 |
CCAR1 Rabbit pAb |
|
A6334-200ul |
Abclonal |
200 ul |
EUR 550.8 |
CCAR1 Rabbit pAb |
|
A6334-20ul |
Abclonal |
20 ul |
EUR 219.6 |
CCAR1 Rabbit pAb |
|
A6334-50ul |
Abclonal |
50 ul |
EUR 267.6 |
CCAR1 Rabbit pAb |
|
E2506334 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CCAR1 Rabbit pAb |
|
E2513595 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
CCAR1 Rabbit pAb |
|
E2122236 |
EnoGene |
100ul |
EUR 225 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
CCAR1 Rabbit pAb |
|
E45R30199N |
EnoGene |
50 ul |
EUR 297.75 |
CCAR1 Rabbit pAb |
|
E45R20175N |
EnoGene |
50 ul |
EUR 297.75 |
CCAR1 Rabbit pAb |
|
MBS8546027-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CCAR1 Rabbit pAb |
|
MBS8546027-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8546027-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8546027-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8546027-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8549123-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CCAR1 Rabbit pAb |
|
MBS8549123-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8549123-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8549123-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
CCAR1 Rabbit pAb |
|
MBS8549123-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
 Anti-CCAR1 Antibody, Rabbit Polyclonal |
|
MBS8119180-01mL |
MyBiosource |
0.1mL |
EUR 300 |
Anti-CCAR1 Antibody, Rabbit Polyclonal |
|
MBS8119180-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
 (Immunofluorescence)) Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence) |
|
IRBAHUCCAR1AP738120UL |
Innovative research |
each |
EUR 247 |
|
|
|
Description: Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence) |
Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence) |
|
IRBAHUCCAR1AP738200UL |
Innovative research |
each |
EUR 383 |
|
|
|
Description: Rabbit Anti Human CCAR1 Polyclonal Affinity Purified (PBS with 0.02% sodium azide, 50% glycerol, pH7.3) (Immunofluorescence) |
 CCAR1 antibody |
|
38833-100ul |
SAB |
100ul |
EUR 302.4 |
 CCAR1 Antibody |
|
36417 |
SAB |
100ul |
EUR 319 |
CCAR1 Antibody |
|
36417-100ul |
SAB |
100ul |
EUR 302.4 |
CCAR1 Antibody |
|
1-CSB-PA816898ESR1HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC; Recommended dilution: WB:1:500-1:2000, IHC:1:20-1:200 |
CCAR1 Antibody |
|
1-CSB-PA816898ESR2HU |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:2000 |
CCAR1 Antibody |
|
1-CSB-PA138742 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against CCAR1. Recognizes CCAR1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
CCAR1 Antibody |
|
C42925-100ul |
Assay Biotech |
100μl |
EUR 217 |
|
Description: CCAR1 Rabbit Polyclonal Antibody |
CCAR1 Antibody |
|
C42925-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
|
Description: CCAR1 Rabbit Polyclonal Antibody |
CCAR1 Antibody |
|
E036417 |
EnoGene |
100μg/100μl |
EUR 255 |
|
Description: Available in various conjugation types. |
CCAR1 Antibody |
|
E309912 |
EnoGene |
200ul |
EUR 275 |
|
Description: Available in various conjugation types. |
CCAR1 Antibody |
|
E96334 |
EnoGene |
100ul |
EUR 255 |
|
Description: Available in various conjugation types. |
CCAR1 Antibody |
|
MBS5400357-01mg |
MyBiosource |
0.1mg |
EUR 445 |
CCAR1 Antibody |
|
MBS5400357-5x01mg |
MyBiosource |
5x0.1mg |
EUR 1855 |
CCAR1 Antibody |
|
MBS7125462-005mL |
MyBiosource |
0.05mL |
EUR 190 |
CCAR1 Antibody |
|
MBS7125462-01mL |
MyBiosource |
0.1mL |
EUR 270 |
CCAR1 Antibody |
|
MBS7125462-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
CCAR1 Antibody |
|
MBS9603815-01mL |
MyBiosource |
0.1mL |
EUR 260 |
CCAR1 Antibody |
|
MBS9603815-02mL |
MyBiosource |
0.2mL |
EUR 305 |
CCAR1 Antibody |
|
MBS9603815-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
CCAR1 Antibody |
|
MBS9412823-01mL |
MyBiosource |
0.1mL |
EUR 305 |
CCAR1 Antibody |
|
MBS9412823-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1230 |
 CCAR2 Polyclonal Antibody |
|
30832 |
SAB |
100ul |
EUR 439 |
CCAR2 Polyclonal Antibody |
|
30832-100ul |
SAB |
100ul |
EUR 302.4 |
CCAR2 Polyclonal Antibody |
|
30832-50ul |
SAB |
50ul |
EUR 224.4 |
 CCAR2 polyclonal antibody |
|
BS8727 |
Bioworld Biotech |
50 ul |
EUR 358 |
|
|
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
CCAR2 Polyclonal Antibody |
|
E-AB-61542-120uL |
Elabscience Biotech |
120uL |
EUR 320 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-61542-200uL |
Elabscience Biotech |
200uL |
EUR 530 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-61542-60uL |
Elabscience Biotech |
60uL |
EUR 200 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-61542-each |
Elabscience Biotech |
each |
Ask for price |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-52105-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-52105-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-52105-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
E-AB-52105-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
|
|
Description: Unconjugated |
CCAR2 Polyclonal Antibody |
|
MBS2562007-002mL |
MyBiosource |
0.02mL |
EUR 135 |
CCAR2 Polyclonal Antibody |
|
MBS2562007-006mL |
MyBiosource |
0.06mL |
EUR 190 |
CCAR2 Polyclonal Antibody |
|
MBS2562007-012mL |
MyBiosource |
0.12mL |
EUR 265 |
CCAR2 Polyclonal Antibody |
|
MBS2562007-02mL |
MyBiosource |
0.2mL |
EUR 415 |
CCAR2 Polyclonal Antibody |
|
MBS2562007-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1835 |
CCAR2 Polyclonal Antibody |
|
MBS2535168-006mL |
MyBiosource |
0.06mL |
EUR 190 |
CCAR2 Polyclonal Antibody |
|
MBS2535168-012mL |
MyBiosource |
0.12mL |
EUR 265 |
CCAR2 Polyclonal Antibody |
|
MBS2535168-02mL |
MyBiosource |
0.2mL |
EUR 415 |
CCAR2 Polyclonal Antibody |
|
MBS2535168-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1835 |
CCAR2 Polyclonal Antibody |
|
MBS9125196-002mL |
MyBiosource |
0.02mL |
EUR 200 |
CCAR2 Polyclonal Antibody |
|
MBS9125196-005mL |
MyBiosource |
0.05mL |
EUR 255 |
CCAR2 Polyclonal Antibody |
|
MBS9125196-01mL |
MyBiosource |
0.1mL |
EUR 345 |
CCAR2 Polyclonal Antibody |
|
MBS9125196-02mL |
MyBiosource |
0.2mL |
EUR 545 |
CCAR2 Polyclonal Antibody |
|
MBS9125196-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
CCAR2 Polyclonal Antibody |
|
MBS9433963-005mL |
MyBiosource |
0.05mL |
EUR 300 |
CCAR2 Polyclonal Antibody |
|
MBS9433963-01mL |
MyBiosource |
0.1mL |
EUR 390 |
CCAR2 Polyclonal Antibody |
|
MBS9433963-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1610 |
CCAR2 Polyclonal Antibody |
|
RD84308A-120uL |
Reddot Biotech |
120μL |
EUR 360 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD84308A-200uL |
Reddot Biotech |
200μL |
EUR 630 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD84308A-60uL |
Reddot Biotech |
60μL |
EUR 204 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD252105A-120uL |
Reddot Biotech |
120μL |
EUR 360 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD252105A-200uL |
Reddot Biotech |
200μL |
EUR 630 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD252105A-20uL |
Reddot Biotech |
20μL |
EUR 109.5 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
CCAR2 Polyclonal Antibody |
|
RD252105A-60uL |
Reddot Biotech |
60μL |
EUR 214.5 |
|
|
|
Description: Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978). |
 CCAR1 Antibody FITC |
|
MBS5400359-01mg |
MyBiosource |
0.1mg |
EUR 560 |
CCAR1 Antibody FITC |
|
MBS5400359-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2380 |
 CCAR1 Antibody BIOTIN |
|
MBS5400358-01mg |
MyBiosource |
0.1mg |
EUR 560 |
CCAR1 Antibody BIOTIN |
|
MBS5400358-5x01mg |
MyBiosource |
5x0.1mg |
EUR 2380 |
 CCAR1 Conjugated Antibody |
|
C36417 |
SAB |
100ul |
EUR 476.4 |
CCAR1 Conjugated Antibody |
|
MBS9446876-01mLAF350 |
MyBiosource |
0.1mL(AF350) |
EUR 480 |
CCAR1 Conjugated Antibody |
|
MBS9446876-01mLAF405 |
MyBiosource |
0.1mL(AF405) |
EUR 480 |
CCAR1 Conjugated Antibody |
|
MBS9446876-01mLAF488 |
MyBiosource |
0.1mL(AF488) |
EUR 480 |
CCAR1 Conjugated Antibody |
|
MBS9446876-01mLAF555 |
MyBiosource |
0.1mL(AF555) |
EUR 480 |
CCAR1 Conjugated Antibody |
|
MBS9446876-01mLBiotin |
MyBiosource |
0.1mL(Biotin) |
EUR 480 |
 CCAR2 Polyclonal Conjugated Antibody |
|
C31969 |
SAB |
100ul |
EUR 476.4 |
CCAR2 Polyclonal Conjugated Antibody |
|
C30832 |
SAB |
100ul |
EUR 476.4 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9442008-01mLAF350 |
MyBiosource |
0.1mL(AF350) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9442008-01mLAF405 |
MyBiosource |
0.1mL(AF405) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9442008-01mLAF488 |
MyBiosource |
0.1mL(AF488) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9442008-01mLAF555 |
MyBiosource |
0.1mL(AF555) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9442008-01mLBiotin |
MyBiosource |
0.1mL(Biotin) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9443142-01mLAF350 |
MyBiosource |
0.1mL(AF350) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9443142-01mLAF405 |
MyBiosource |
0.1mL(AF405) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9443142-01mLAF488 |
MyBiosource |
0.1mL(AF488) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9443142-01mLAF555 |
MyBiosource |
0.1mL(AF555) |
EUR 480 |
CCAR2 Polyclonal Conjugated Antibody |
|
MBS9443142-01mLBiotin |
MyBiosource |
0.1mL(Biotin) |
EUR 480 |
 (IHC,ELISA)) Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA) |
|
IRBAMLCCAR2AAP105120UL |
Innovative research |
each |
EUR 259 |
|
|
|
Description: Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA) |
Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA) |
|
IRBAMLCCAR2AAP105200UL |
Innovative research |
each |
EUR 403 |
|
|
|
Description: Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4) (IHC,ELISA) |
(IHC, ELISA)) Rabbit Anti CCAR2 Polyclonal Antigen affinity Purified (PBS with 0.05% NaN3 and 40% Glycerol, pH7.4)(IHC, ELISA) |
|
MBS8423048-INQUIRE |
MyBiosource |
INQUIRE |
Ask for price |
 CCAR1 Antibody - middle region |
|
MBS3221149-01mL |
MyBiosource |
0.1mL |
EUR 455 |
CCAR1 Antibody - middle region |
|
MBS3221149-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1995 |
 C163A Rabbit Polyclonal Antibody |
|
BT-AP00915-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
BT-AP00915-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
BT-AP00915-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
BT-AP00916-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
BT-AP00916-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
BT-AP00916-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
|
|
Description: It is uncertain whether Met-1 or Met-6 is the initiator.|disease:The soluble form (sCD163) in plasma is a novel parameter in diseases affecting macrophage function and monocyte/macrophage load in the body. The concentration of sCD163 is probably reflecting the number of macrophages of the 'alternative macrophage activation' phenotype with a high CD163 expression playing a major role in dampening the inflammatory response and scavenging components of damaged cells. This has initiated a number of clinical studies for evaluation of sCD163 as a disease marker in inflammatory conditions e.g. infection| autoimmune disease| transplantation| atherosclerosis and cancer.|The SRCR domain 3 mediates calcium-sensitive interaction with hemoglobin/haptoglobin complexes.|Acute phase-regulated receptor involved in clearance and endocytosis of hemoglobin/haptoglobin complexes by macrophages and may thereby protect tissues from free hemoglobin-mediated oxidative damage. May play a role in the uptake and recycling of iron| via endocytosis of hemoglobin/haptoglobin and subsequent breakdown of heme. Binds hemoglobin/haptoglobin complexes in a calcium-dependent and pH-dependent manner. Exhibits a higher affinity for complexes of hemoglobin and multimeric haptoglobin of HP*1F phenotype than for complexes of hemoglobin and dimeric haptoglobin of HP*1S phenotype. Induces a cascade of intracellular signals that involves tyrosine kinase-dependent calcium mobilization| inositol triphosphate production and secretion of IL6 and CSF1. Isoform 3 exhibits the higher capacity for ligand endocytosis and the more pronounced surface expression when expressed in cells.|After shedding| the soluble form (sCD163) may play an anti-inflammatory role| and may be a valuable diagnostic parameter for monitoring macrophage activation in inflammatory conditions.|induction:Induced by anti-inflammatory mediators such as glucocorticoids| IL6 and IL10; suppressed by proinflammatory mediators like lipopolysaccharide (LPS)| Interferon gamma/IFNG| and tumor necrosis factor alpha.|miscellaneous:Intravenous lipopolysaccharide (LPS) produces a rapid rise of sCD163 in plasma of patient as it induces metalloproteinase-mediated shedding from monocytes surface. Long-term LPS infusion finally increases expression of the membrane-bound form on circulating monocytes.|PTM:A soluble form (sCD163) is produced by proteolytic shedding which can be induced by lipopolysaccharide| phorbol ester and Fc region of immunoglobulin gamma. This cleavage is dependent on protein kinase C and tyrosine kinases and can be blocked by protease inhibitors. The shedding is inhibited by the tissue inhibitor of metalloproteinase TIMP3| and thus probably induced by membrane-bound metalloproteinases ADAMs.|PTM:Phosphorylated.|Contains 9 SRCR domains.|subcellular location:Isoform 1 and isoform 2 show a lower surface expression when expressed in cells.|subunit:Interacts with CSNK2B.|tissue specificity:Expressed in monocytes and mature macrophages such as Kupffer cells in the liver| red pulp macrophages in the spleen| cortical macrophages in the thymus| resident bone marrow macrophages and meningeal macrophages of the central nervous system. Expressed also in blood. Isoform 1 is the lowest abundant in the blood. Isoform 2 is the lowest abundant in the liver and the spleen. Isoform 3 is the predominant isoform detected in the blood.| |
C163A Rabbit Polyclonal Antibody |
|
JOT-AP00915-100ul |
Jotbody |
100ul |
EUR 220 |
|
|
C163A Rabbit Polyclonal Antibody |
|
JOT-AP00915-50ul |
Jotbody |
50ul |
EUR 144 |
|
|
C163A Rabbit Polyclonal Antibody |
|
JOT-AP00916-100ul |
Jotbody |
100ul |
EUR 220 |
|
|
C163A Rabbit Polyclonal Antibody |
|
JOT-AP00916-50ul |
Jotbody |
50ul |
EUR 144 |
|
|
 C2C4A Rabbit Polyclonal Antibody |
|
JOT-AP00934-100ul |
Jotbody |
100ul |
EUR 220 |
C2C4A Rabbit Polyclonal Antibody |
|
JOT-AP00934-50ul |
Jotbody |
50ul |
EUR 144 |
 C144A Rabbit Polyclonal Antibody |
|
JOT-AP06670-100ul |
Jotbody |
100ul |
EUR 220 |
C144A Rabbit Polyclonal Antibody |
|
JOT-AP06670-50ul |
Jotbody |
50ul |
EUR 144 |
 CC74A Rabbit Polyclonal Antibody |
|
JOT-AP07265-100ul |
Jotbody |
100ul |
EUR 220 |
CC74A Rabbit Polyclonal Antibody |
|
JOT-AP07265-50ul |
Jotbody |
50ul |
EUR 144 |
 CC50A Rabbit Polyclonal Antibody |
|
ES10504-100ul |
ELK Biotech |
100ul |
EUR 124 |
|
|
|
Description: WB, ELISA |
CC50A Rabbit Polyclonal Antibody |
|
ES10504-50ul |
ELK Biotech |
50ul |
EUR 74 |
|
|
|
Description: WB, ELISA |
CCAR1 Rabbit Polyclonal Antibody
